NCT04560127 2025-07-10
Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 2 Active not recruiting
Clinical Trials
1 trialsActive not recruiting × Radioactive Iodine-refractory Differentiated Thyroid Cancer × Endocrine × Clear all